- Home
- QTTB vs LFS Comparison
QTTB vs LFS Comparison
Compare QTTB & LFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | LFS |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Japan |
| Employees | N/A | 1055 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 92.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | QTTB | LFS |
|---|---|---|
| Price | $5.85 | $3.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 227.6K | 56.2K |
| Earning Date | 05-14-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $1.58 |
| 52 Week High | $8.05 | $12.49 |
Technical Indicators
Market Signals| Indicator | QTTB | LFS |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 80.84 |
| Support Level | $5.51 | $1.69 |
| Resistance Level | $6.37 | $3.89 |
| Average True Range (ATR) | 0.54 | 0.30 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 56.79 | 66.41 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.